Abstracts tagged "anti-CCP antibodies"

Abstract Number: 410 • 2013 ACR/ARHP Annual Meeting
Correlation of Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis
Lourdes Nuñez Atahualpa¹, Mauricio Figuroa Sanchez¹, Daniel Alberto Rocha Muñoz², Raul Vargas Ramirez³, Beatriz Teresita Martin Marquez⁴, Jorge Ivan Gamez Nava⁵, Laura González López⁶, Erika Martínez García³, Esther Sanchez Corona³, Marcelo Petri⁴, Rosa Navarro Hernandez³, Veronica Gonzalez Diaz⁷, Jorge Aguilar Arreola⁸, Ana Guisllaine Bernard Medina⁹, Alejandra Nuñez Atahualpa¹⁰, Javier Andrade Garduño¹⁰, Eduardo Gomez Bañuelos³ and Monica Vazquez Del Mercado^4,8, ¹Radiology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ²Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ³CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁴Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, ⁶Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, ⁷Reumatologia, Antiguo Hospital Civil de Guadalajara - Fray Antonio Alcalde, Guadalajara, Mexico, ⁸Rheumatology, Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, ⁹Rheumatology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ¹⁰Universidad Autónoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The main cause of death in rheumatoid arthritis patients are cardiovascular events which cannot be entirely explained by traditional risk factors, suggesting, that systemic…
Abstract Number: 2660 • 2013 ACR/ARHP Annual Meeting
Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Ryan W. Gan¹, Kendra A. Young¹, Gary O. Zerbe², M. Kristen Demoruelle³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Michael J. Clare-Salzler¹⁰, Kevin D. Deane³, V. Michael Holers¹¹ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology Section, The University of Chicago, Chicago, IL, ¹⁰Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and circulating autoantibodies, which can be present in serum years prior to RA diagnosis and can…
Abstract Number: 2412 • 2013 ACR/ARHP Annual Meeting
Anti-CCP Antibodies and Increased Cartilage Turnover In Patients Developing Rheumatoid Arthritis
Carl Turesson¹, Christina Book², Ulf Bergström², Lennart Truedsson³, Lennart Jacobsson² and Tore Saxne⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Autoantibodies may be detected years before the onset of rheumatoid arthritis (RA). We have previously shown that levels of Cartilage oligomeric matrix protein (COMP),…
Abstract Number: 2278 • 2013 ACR/ARHP Annual Meeting
Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Emily H. Glynn¹, Mark H. Wener² and Michael Astion³, ¹Laboratory Medicine, University of Washington, Seattle, WA, ²Rheumatology & Lab Med, University of Washington, Seattle, WA, ³Department of Laboratories, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Anti-citrullinated peptide antibodies (ACPA) are more specific and have a superior positive predictive value for diagnosis of rheumatoid arthritis (RA) compared to RF. The…
Abstract Number: 2197 • 2013 ACR/ARHP Annual Meeting
High Titer IgG Anti-Cyclic Citrullinated Peptide Antibodies Are Associated With Joint Destruction In Juvenile Idiopathic Arthritis Patients
Brooke Gilliam, Lance Feller and Terry L. Moore, Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: IgG anti-cyclic citrullinated peptide (anti-CCP) antibodies have been identified as an important indicator of destructive disease in juvenile idiopathic arthritis (JIA), as is the…
Abstract Number: 1586 • 2013 ACR/ARHP Annual Meeting
Defining Hand Arthritis In Systemic Lupus Erythematosus, From An Ultrasound, Magnetic Resonance Imaging and Antibody Status Perspective
Elisabeth M.A Ball¹, Arthur Grey², Ai Lyn Tan³, Eiji Fukuba⁴, Gunter Steiner⁵, Dennis McGonagle⁶, Aubrey Bell⁷ and Madeleine Rooney⁸, ¹Rheumatology, Queens' University/Musgrave Park Hospital, Belfast, United Kingdom, ²Rheumatology, Musgrave Park Hospital, Belfast, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Radiology, Shimane University, Izuma, Japan, ⁵Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ⁷Rheumatology Unit, Musgrave Park Hospital, Belfast, United Kingdom, ⁸Medicine, Queens University Belfast, Belfast, United Kingdom
Background/Purpose: Musculoskeletal involvement in systemic lupus erythematosus (SLE) is common but poorly characterised with only a few Magnetic Resonance Imaging (MRI) or ultrasound (US) studies…
Abstract Number: 2615 • 2012 ACR/ARHP Annual Meeting
Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination
Anne C. Bay-Jensen¹, Morten Asser Karsdal², Efstathios Vassiliadis³, Stephanie Wichuk⁴, Zheng Zhao⁵, Robert GW Lambert⁶, Rik Lories⁷, Claus Christiansen⁸ and Walter P. Maksymowych⁹, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁶Radiology, University of Alberta, Edmonton, AB, Canada, ⁷Laboratory of Tissue Homeostasis and Disease - SBE Research Center, KU Leuven, Leuven, Belgium, ⁸CCBR, Ballerup, Denmark, ⁹Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis (RA) is considered an anti-CCP positive disease whereas ankylosing spondylitis (AS) is considered an anti-CCP negative disease. Anti-CCP has prognostic capacity in…
Abstract Number: 1211 • 2012 ACR/ARHP Annual Meeting
ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre², Rosario M. Carretero-Prieto¹, Antonio Rodriguez-Ariza³, Nuria Barbarroja¹, Pilar Font¹, Francisco Martinez², Inmaculada Gomez-Gracia², Mª Jose Cuadrado⁴ and Eduardo Collantes-Estevez², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role…
Abstract Number: 2581 • 2012 ACR/ARHP Annual Meeting
Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Carolin Hecht¹, Stephanie Finzel¹, Matthias Englbrecht¹, Sarah Schmidt¹, Juergen Rech², Elizabeth Araujo¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti- citrullinated protein antibodies (ACPA) are known to be associated with joint destruction and a more severe disease course in rheumatoid arthritis (RA) patients.…
Abstract Number: 1193 • 2012 ACR/ARHP Annual Meeting
Podoplanin Expression in Rheumatoid Stroma Correlates with Lymphoid Neogenesis and Is Downregulated by Anti-TNF-α Therapy
Regina Faré¹, Elena Izquierdo¹, Manuel J. Del Rey¹, Raquel Celis², Alicia Usategui¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) expand and undergo phenotypic changes that contribute to chronic inflammation and joint destruction. Podoplanin (Pdp) is a…
Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kuniki Amano², Kazuhiko Hatta³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
Abstract Number: 1010 • 2012 ACR/ARHP Annual Meeting
Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Stephanie Finzel¹, Veronika Lang², Arnd Kleyer¹, Juergen Rech³, Bernhard Manger¹, Elizabeth Araujo¹, Axel J. Hueber⁴, Ulrike Harre⁵ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly…
Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting
Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Aase Haj Hensvold¹, Saedis Saevarsdottir*², Wanyiang Li*³, Vivianne Malmström⁴, Guy Cavet⁵, Lars Klareskog⁶ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
*equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].